Blood-based inflammatory biomarkers in ovarian cancer: addressing the challenge of early detection, metastasis, and prognostic stratification.
- 1Division of Haematology, Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe.
- 2Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Abstract
Ovarian cancer remains a major cause of gynaecological cancer mortality, largely because early disease is frequently asymptomatic and reliable population-based screening remains unavailable. Systemic inflammation is increasingly recognised as an important component of ovarian cancer biology, linking tumour progression, immune dysregulation, angiogenesis, metastasis and treatment resistance. This narrative review critically evaluates blood-based inflammatory biomarkers, including C-reactive protein, interleukin-6, interleukin-8, tumour necrosis factor-α, fibrinogen, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index (SII), systemic inflammation response index (SIRI) and pan-immune-inflammation value (PIV), across early detection, metastatic assessment, treatment decision-making and prognostic stratification. Available evidence indicates that elevated inflammatory indices are consistently associated with advanced disease and adverse outcomes, although substantial heterogeneity exists in biomarker thresholds, populations, timing of measurement and analytical approaches. Recent evidence also suggests that preoperative NLR and SII may contribute to treatment selection, including neoadjuvant chemotherapy, although prognostic independence is not consistently demonstrated. Importantly, inflammatory biomarkers lack sufficient specificity for standalone ovarian cancer screening and should not replace CA-125, HE4, imaging or histopathological assessment. Their greatest clinical potential lies in multimarker models integrating systemic inflammatory, tumour-specific, molecular and clinical variables. Future research should prioritise prospective multicentre validation, standardised thresholds, longitudinal assessment and clinically interpretable prediction models to determine whether inflammatory profiling can advance precision risk stratification and treatment selection in ovarian cancer.
Related
- Stemness-Associated Biomarkers in Breast Cancer Liver Metastasis: Hepatic Adaptation, Prognostic Relevance, and Monitoring
- RAS Mutations as Prognostic Biomarkers in Digestive Cancers: From Binary Classification to Variant-Specific and Context-Dependent Risk Stratification
- Inflammatory Biomarkers and Left Atrial Remodelling for Early Risk Stratification of 6-Month Readmission in Ischaemic and Idiopathic Dilated Cardiomyopathy
- Addressing unmet clinical needs in treatment-resistant breast cancer: expanding the diagnostic–prognostic landscape through next-generation inflammatory signatures
- Reclassifying renal cell carcinoma with pathologic lymph node metastasis: An approach to refining prognostic stratification in patients with AJCC III and IV stages
BibTeX
@article{obeagu2026bloodbased,
title = {{Blood-based inflammatory biomarkers in ovarian cancer: addressing the challenge of early detection, metastasis, and prognostic stratification.}},
author = {Emmanuel Ifeanyi Obeagu},
journal = {Oncology reviews},
year = {2026},
month = oct,
doi = {10.3389/or.2026.1914468},
url = {https://europepmc.org/article/MED/42909193},
note = {CC BY},
}
RIS
TY - JOUR
TI - Blood-based inflammatory biomarkers in ovarian cancer: addressing the challenge of early detection, metastasis, and prognostic stratification.
AU - Emmanuel Ifeanyi Obeagu
PY - 2026
DA - 2026/10/07
JO - Oncology reviews
DO - 10.3389/or.2026.1914468
UR - https://europepmc.org/article/MED/42909193
AB - Ovarian cancer remains a major cause of gynaecological cancer mortality, largely because early disease is frequently asymptomatic and reliable population-based screening remains unavailable. Systemic inflammation is increasingly recognised as an important component of ovarian cancer biology, linking tumour progression, immune dysregulation, angiogenesis, metastasis and treatment resistance. This narrative review critically evaluates blood-based inflammatory biomarkers, including C-reactive protein, interleukin-6, interleukin-8, tumour necrosis factor-α, fibrinogen, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index (SII), systemic inflammation response index (SIRI) and pan-immune-inflammation value (PIV), across early detection, metastatic assessment, treatment decision-making and prognostic stratification. Available evidence indicates that elevated inflammatory indices are consistently associated with advanced disease and adverse outcomes, although substantial heterogeneity exists in biomarker thresholds, populations, timing of measurement and analytical approaches. Recent evidence also suggests that preoperative NLR and SII may contribute to treatment selection, including neoadjuvant chemotherapy, although prognostic independence is not consistently demonstrated. Importantly, inflammatory biomarkers lack sufficient specificity for standalone ovarian cancer screening and should not replace CA-125, HE4, imaging or histopathological assessment. Their greatest clinical potential lies in multimarker models integrating systemic inflammatory, tumour-specific, molecular and clinical variables. Future research should prioritise prospective multicentre validation, standardised thresholds, longitudinal assessment and clinically interpretable prediction models to determine whether inflammatory profiling can advance precision risk stratification and treatment selection in ovarian cancer.
SN - 1970-5565
SN - 1970-5557
ER -